Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (21-30 of 242) with videos related to

Pageof 25
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 16, 2007
Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomyTatsuro Okamoto, Riichiroh Maruyama, Takashi Seto, et al.
International Journal of Clinical Oncology|November 19, 2004
Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II studyTakashi Seto, Yoriko Takezako, Hiroko Nakamura, et al.
Future Oncology (London, England)|June 9, 2016
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studiesShinji Atagi, Koichi Goto, Takashi Seto, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|April 17, 2008
Pulmonary typical carcinoid tumor and liver metastasis with hypermetabolism on 18-fluorodeoxyglucose PET: a case reportRyuichi Suemitsu, Riichiroh Maruyama, Kenichi Nishiyama, et al.
Expert Review of Anticancer Therapy|June 10, 2021
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistanceNaoki Haratake, Gouji Toyokawa, Takashi Seto, et al.
Thoracic Cancer|February 3, 2021
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutationShinkichi Takamori, Taichi Matsubara, Takatoshi Fujishita, et al.
Respirology (Carlton, Vic.)|January 21, 2006
Gefitinib-induced lung injury successfully treated with high-dose corticosteroidsTakashi Seto, Nobuhiko Seki, Kazutsugu Uematsu, et al.
Japanese Journal of Clinical Oncology|May 29, 2010
Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapyYukito Ichinose, Takashi Seto, Yutaka Nishiwaki, et al.
BMC Pulmonary Medicine|January 10, 2022
Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant dataYuri Taniguchi, Hiroaki Okamoto, Tsuneo Shimokawa, et al.
Thoracic Cancer|October 24, 2021
Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapyTaichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, et al.
Pageof 25

Showing results (21-30 of 242) with videos related to

Sort By:
Pageof 25
Lung Cancer (Amsterdam, Netherlands)|February 16, 2007
Multiple pulmonary metastases of lung adenocarcinoma to a different ipsilateral lobe after pulmonary lobectomyTatsuro Okamoto, Riichiroh Maruyama, Takashi Seto, et al.
International Journal of Clinical Oncology|November 19, 2004
Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II studyTakashi Seto, Yoriko Takezako, Hiroko Nakamura, et al.
Future Oncology (London, England)|June 9, 2016
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studiesShinji Atagi, Koichi Goto, Takashi Seto, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|April 17, 2008
Pulmonary typical carcinoid tumor and liver metastasis with hypermetabolism on 18-fluorodeoxyglucose PET: a case reportRyuichi Suemitsu, Riichiroh Maruyama, Kenichi Nishiyama, et al.
Expert Review of Anticancer Therapy|June 10, 2021
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistanceNaoki Haratake, Gouji Toyokawa, Takashi Seto, et al.
Thoracic Cancer|February 3, 2021
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutationShinkichi Takamori, Taichi Matsubara, Takatoshi Fujishita, et al.
Respirology (Carlton, Vic.)|January 21, 2006
Gefitinib-induced lung injury successfully treated with high-dose corticosteroidsTakashi Seto, Nobuhiko Seki, Kazutsugu Uematsu, et al.
Japanese Journal of Clinical Oncology|May 29, 2010
Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapyYukito Ichinose, Takashi Seto, Yutaka Nishiwaki, et al.
BMC Pulmonary Medicine|January 10, 2022
Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant dataYuri Taniguchi, Hiroaki Okamoto, Tsuneo Shimokawa, et al.
Thoracic Cancer|October 24, 2021
Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapyTaichi Matsubara, Shinkichi Takamori, Takatoshi Fujishita, et al.
Pageof 25